Sera Prognostics, Inc. (SERA)
| Market Cap | 317.60M |
| Revenue (ttm) | 30,000 |
| Net Income (ttm) | -21.51M |
| Shares Out | 30.51M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,761 |
| Open | 10.73 |
| Previous Close | 10.75 |
| Day's Range | 10.25 - 10.73 |
| 52-Week Range | 7.61 - 15.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 18.00 (+72.9%) |
| Est. Earnings Date | Nov 15, 2021 |
About SERA
Sera Prognostics is a women’s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Our first commercial product, the PreTRM test, is ...
Financial Performance
In 2020, SERA's revenue was $25,000, a decrease of -30.56% compared to the previous year's $36,000. Losses were -$19.85 million, 20.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SERA stock is "Strong Buy." The 12-month stock price forecast is 18.00, which is an increase of 72.91% from the latest price.
News
Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer
Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy
Sera Prognostics to be Added to Russell 2000 Index
SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...
Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer
SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...
Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...
Sera Prognostics Reports Second Quarter 2021 Financial Results
SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...
Sera Prognostics Announces Pricing of Initial Public Offering
SALT LAKE CITY, July 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker in...
Sera Prognostics IPO Registration Document (S-1)
Sera Prognostics, Inc. has filed to go public with an IPO on the NASDAQ.
Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk...
The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time